AbbVie, Thermo Fisher Scientific, and Vertex Pharmaceuticals are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies that apply living organisms or molecular biology techniques to develop medical therapies, diagnostics, or agricultural products. Because these firms often invest heavily in research and face lengthy regulatory approval processes, their stock prices can be highly volatile and closely tied to clinical trial results and government decisions. Investors in biotech stocks seek the potential for significant returns but must also be prepared for the risks of scientific setbacks and regulatory delays. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
NYSE ABBV traded down $4.90 during trading hours on Friday, reaching $181.89. The company had a trading volume of 29,262,557 shares, compared to its average volume of 6,249,513. The company has a current ratio of 0.76, a quick ratio of 0.64 and a debt-to-equity ratio of 44.14. The stock has a market capitalization of $321.29 billion, a P/E ratio of 77.40, a price-to-earnings-growth ratio of 1.21 and a beta of 0.50. The stock has a 50-day moving average of $186.21 and a 200 day moving average of $188.01. AbbVie has a 1-year low of $163.52 and a 1-year high of $218.66.
Read Our Latest Research Report on ABBV
Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Shares of NYSE:TMO traded down $4.45 during mid-day trading on Friday, reaching $407.67. 3,922,604 shares of the company were exchanged, compared to its average volume of 1,951,845. The firm has a market cap of $153.89 billion, a price-to-earnings ratio of 23.91, a P/E/G ratio of 2.15 and a beta of 0.78. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.77 and a quick ratio of 1.38. Thermo Fisher Scientific has a 1 year low of $385.46 and a 1 year high of $627.88. The firm's 50-day simple moving average is $409.74 and its 200 day simple moving average is $483.23.
Read Our Latest Research Report on TMO
Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Shares of NASDAQ VRTX traded down $2.10 during trading on Friday, reaching $441.30. The stock had a trading volume of 3,615,473 shares, compared to its average volume of 1,418,238. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.29 and a current ratio of 2.65. The company has a market cap of $113.33 billion, a P/E ratio of -112.58 and a beta of 0.41. Vertex Pharmaceuticals has a fifty-two week low of $377.85 and a fifty-two week high of $519.88. The business's 50-day moving average price is $454.50 and its 200-day moving average price is $458.76.
Read Our Latest Research Report on VRTX
Read More
Before you consider AbbVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.
While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
